Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic ...

The results could pave the way for the drug, a monoclonal antibody called ponsegromab, to become the first treatment approved ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 25. David Risinger ...

This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer cachexia. Meanwhile, IMPACT Therapeutics senaparib has seen its phase ...

Therefore, the drug which is a monoclonal antibody called ponsegromab could become the first treatment approved in the U.S. specifically for this condition. This would translate to Pfizer saving ...

The company also recently reported positive phase 2 results for ponsegromab, a potential medicine for cancer cachexia -- cachexia is a condition that can cause significant weight and muscle loss ...